Is a
Patent attributes
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
February 5, 2019
Patent Application Number
15071489
Date Filed
March 16, 2016
Patent Citations Received
Patent Primary Examiner
Patent abstract
The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
